Nektar Therapeutics Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Nektar Therapeutics (NKTR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $43.60 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-13
- Nektar Therapeutics share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $43.60, a 4092.31% increase from fiscal 2024.
- Nektar Therapeutics share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.04, a 103.92% increase from fiscal 2023.
- Nektar Therapeutics share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $0.51, a 89.29% decline from fiscal 2022.
- Nektar Therapeutics share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.76, a 67.06% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $43.60 10-K · filed 2026-03-13 |
| 2024-12-31 | $1.04 10-K · filed 2025-03-14 |
| 2023-12-31 | $0.51 10-K · filed 2024-03-05 |
| 2022-12-31 | $4.76 10-K · filed 2023-02-28 |
| 2021-12-31 | $14.45 10-K · filed 2022-03-01 |
| 2020-12-31 | $19.15 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |